KIR3DL1 and neoplasm: Treatment with BEMPEG plus nivolumab showed a trend toward increased PFS for these KIR-ligand present TNBC patients (p = 0.06) (Fig. 2A) and significantly improved OR (p = 0.009; 36.4 vs. 0%) and tumor shrinkage (p = 0.02; median change −23.5 vs. +12.8%) as compared to their KIR-ligand missing counterparts (Fig. 2B, C).